이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Invivyd 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Bill Duke

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	1.3yrs
이사회 평균 재임 기간	1.8yrs

최근 관리 업데이트

Recent updates

We're Interested To See How Adagio Therapeutics (NASDAQ:ADGI) Uses Its Cash Hoard To Grow

Feb 19

Adagio: A COVID-19 Play With Big Potential On Possible Treatment And Prevention

Feb 16

Adagio Therapeutics: The Market Is Too Crowded For Its Lead Drug Candidate

Nov 29

CEO

Bill Duke (52 yo)

less than a year

테뉴어

Mr. William E. Duke, Jr., also known as Bill, M.B.A., serves as Chief Financial Officer of Invivyd, Inc. since September 2023 and serves as its Principal Executive Officer since May 2024. Mr. Duke served a...

리더십 팀

이름	위치	테뉴어	보상	소유권
Robert Allen	Chief Scientific Officer	1.3yrs	US$2.16m	0% $ 0
Jill Andersen	Chief Legal Officer & Corporate Secretary	2.7yrs	US$2.08m	0.0023% $ 3.0k
William Duke	CFO & Principal Executive Officer	less than a year	데이터 없음	데이터 없음
Stacy Price	Chief Technology & Manufacturing Officer	1.3yrs	데이터 없음	데이터 없음
Scott Young	Senior Vice President of Investor Relations & Corporate Communications	no data	데이터 없음	데이터 없음
Julie Green	Chief Human Resources Officer	1.5yrs	데이터 없음	데이터 없음
Mark Wingertzahn	Senior Vice President of Clinical Development & Medical Affairs	less than a year	데이터 없음	데이터 없음
Timothy Lee	Chief Commercial Officer	less than a year	데이터 없음	데이터 없음

1.3yrs

평균 재임 기간

52.5yo

평균 연령

경험이 풍부한 관리: IVVD 의 관리팀은 경험 (평균 재직 기간 1.2 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Terrance McGuire	Director	3.8yrs	US$97.13k	0% $ 0
Kevin McLaughlin	Independent Director	less than a year	데이터 없음	데이터 없음
Marc Elia	Independent Chairperson of the Board	2.1yrs	US$138.63k	0% $ 0
Christine Lindenboom	Independent Director	1.8yrs	US$80.44k	0% $ 0
Srishti Gupta	Independent Director	less than a year	데이터 없음	데이터 없음
Tamsin Berry	Director	2.1yrs	US$93.13k	0% $ 0
Sara Cotter	Independent Director	less than a year	US$106.56k	0.00084% $ 1.1k

1.8yrs

평균 재임 기간

48yo

평균 연령

경험이 풍부한 이사회: IVVD 의 이사회는 경험(평균 재직 기간 1.7 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Invivyd 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Invivyd, Inc. Announces Management Changes

Invivyd, Inc. Elects Two New Independent Members to its Board of Directors

Invivyd, Inc., Annual General Meeting, May 21, 2024

Invivyd, Inc. Announces CEO Changes

Invivyd, Inc. Announces CEO Transition

Invivyd, Inc. Appoints William Duke as Chief Financial Officer

Recent updates

Invivyd Announces General Alignment with U.S. FDA on A Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies

Invivyd, Inc. Announces Management Changes

Invivyd, Inc. Elects Two New Independent Members to its Board of Directors

Forecast to breakeven in 2026

Invivyd, Inc. to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback

Invivyd, Inc., Annual General Meeting, May 21, 2024

Invivyd, Inc. Receives Healthcare Common Procedure Coding System Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services Covering Pemgarda

Invivyd, Inc. Receives Healthcare Common Procedure Coding System Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services Covering Pemgarda

Invivyd, Inc. Announces CEO Changes

Invivyd, Inc. Announces CEO Transition

New minor risk - Profitability

No longer forecast to breakeven

Consensus revenue estimates fall by 13%

Invivyd, Inc. Provides Earnings Guidance for the Year 2024

Forecast breakeven date moved forward to 2025

Invivyd, Inc. Provides Earnings Guidance for the Year 2024

Consensus revenue estimates increase by 64%

Is Invivyd (NASDAQ:IVVD) In A Good Position To Invest In Growth?

Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19

New minor risk - Shareholder dilution

Forecast to breakeven in 2026

Invivyd, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Invivyd, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Invivyd, Inc. Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19

Invivyd, Inc. Appoints William Duke as Chief Financial Officer

Invivyd, Inc. Appoints Sara Cotter to Board of Directors

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Invivyd, Inc. Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222

Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely?

Invivyd, Inc. Announces Executive Changes

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Invivyd, Inc

Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer

Is Invivyd (NASDAQ:IVVD) In A Good Position To Deliver On Growth Plans?

Less than half of directors are independent

Invivyd Announces Board Changes

Invivyd, Inc. Announces Executive Changes

Invivyd appoints interim CFO, makes headcount changes

Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in Vitro Data Against Omicron Variants

Adagio Therapeutics changes name to Invivyd, generates COVID-19 antibodies

Adagio Therapeutics GAAP EPS of -$0.47

We're Keeping An Eye On Adagio Therapeutics' (NASDAQ:ADGI) Cash Burn Rate

Adagio Therapeutics, Inc. Appoints David Hering Permanent Chief Executive Officer

Less than half of directors are independent

Adagio names David Hering as permanent CEO and Director

Howard Mayer, M.D. Notifies Adagio Therapeutics, Inc. of His Decision to Resign from the Board of Directors

Adagio Therapeutics, Inc.(NasdaqGM:ADGI) dropped from Russell 2000 Growth Index

Adagio Therapeutics, Inc. Elects Class I Directors

Adagio Therapeutics, Inc., Annual General Meeting, Jun 22, 2022

Adagio Therapeutics, Inc., Annual General Meeting, Jun 22, 2022

No longer forecast to breakeven

Mithril Capital Provides Information to Shareholders of Adagio Therapeutics

Adagio Therapeutics, Inc. Provides Update on Timing of Adintrevimab EUA Request

No longer forecast to breakeven

No longer forecast to breakeven

Mithril Capital Management Communicates with Adagio Therapeutics

Adagio Therapeutics, Inc. Announces Executive Changes, Effective March 25, 2022

Adagio's Round Trip

Adagio Therapeutics Announces ADG20 Development Plans and Pipeline Updates

Adagio Therapeutics, Inc. Announces Executive Changes

We're Interested To See How Adagio Therapeutics (NASDAQ:ADGI) Uses Its Cash Hoard To Grow

Adagio: A COVID-19 Play With Big Potential On Possible Treatment And Prevention

Adagio Therapeutics, Inc. Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants and Outlines Initiatives to Address Omicron

Adagio Therapeutics: The Market Is Too Crowded For Its Lead Drug Candidate

Adagio Therapeutics, Inc. Reports Updates on Its Lead Covid-19 Antibody Program, ADG20

Adagio Therapeutics, Inc. Announces the Independent Data Monitoring Committee (IDMC) for the EVADE Phase 2/3 Trial of ADG20 for the Prevention of COVID-19

Adagio Therapeutics, Inc. has completed an IPO in the amount of $309.4 million.

CEO